Jakub NICPON, Krzysztof MARYCZ, Jakub GRZESIAK, Agnieszka SMIESZEK, NEZİR YAŞAR TOKER

The advantages of autologus adipose derived mesenchymal stem cells (AdMSCs) over the non-steroidal anti-inflammatory drugs (NSAIDs) application for degenerative elbow joint disease treatment in dogs twelve cases

Bu çalışma klinik olarak dirsek ekleminde osteoartritis tespit edilen, standart non-steroidal anti inflammatuar ilaçlardan (NSAIA) türetilmiş terapötik ilaçla tedavi edilen 5-11 yaş arasında, oniki (7 erkek, 5 dişi) köpekte, adipoz doku orijinli otolog mezenkimal kök hücrelerin (ADkOMKH) etkinliğini karşılaştırmak için yapılmıştır. Teşhisten önce hayvanlara 3 ay boyunca herhangi bir uygulama yapılmamıştır. Deneysel gruptaki bireyler adipoz kökenli otolog mezenkimal kök hücrelerle tedavi edildi, buna karşın kontrol grubun bireylerine Mavacoxib (Trocoxil) uygulandı. Uygulamanın 0, 60, 90 ve 180. günlerinde, her bir birey klinik olarak muayene edildi. Ayrıca, tüm hayvanlardan 0, 60, 90 ve 180. günlerde ilgili eklemlerden alınan siynovial sıvıların analizi yapıldı. Ayrıca, 0 ve 180. günlerde CT analizi yapıldı. Dirsek eklemi dejenerasyonunda (OA); ADkOMKH ile tedaviye alınan hayvanlarda; ağrı, yürürken oluşan sertlikler, topallıklar gibi klinik semptomlar hafifledi. Kontrol grubundaki hayvanlar da deneyin ilk peryodun da gelişme görülmesinin aksine, OA semptom’unun NSAIA uygulamasından 90 gün sonra tekrarladığı gözlendi. Bu çalışma, sadece klinik incelemenin görüntüsünü anlatan bir çalışma değil aynı zamanda siynovial sıvı analizi ve CT değerlendirilmesine dayanan ilk çalışmadır. Otolog mezenkimal kök hücrelerin uygulanması metodun güvenliğini onaylayarak, herhangi bir istenmeyen reaksiyon sergilemedi. Bu çalışma, AdMSC uygulamasının köpeklerde osteofitik gerileme olmaksızın; dirsek eklemi osteoartritisindeki verimliliği artırmış, klinik bulguları ve hasta kondüsyonunu geliştirmiştir.

Köpeklerde dejeneratif dirsek eklemi bozukluğu tedavisinde non-steroidal antiinflamatuar Ajan (NSAIA) uygulanmasından sonra adipoz doku kökenli otolog mezenkimal kök hücrelerin (ADkOMKH) faydası oniki olgu

In the present study based on clinical case reports, twelve dogs (7 males, 5 females) between the ages of 5 and 11 years old, with clinically diagnosed osteoarthritis of the elbow joint were undertaken for comparison of the therapeutic effect derived from the standard non-steroidal antiinflammatory drug (NSAIDs) treatment with novel, autologous adipose-derived mesenchymal stem cell (AdMSCs) application. Animals were not under any treatment for 3 last months before the diagnosis. Individuals from experimental group were treated with autologous adipose-derived mesenchymal stem cells, while individuals from control group received Mavacoxib (Trocoxil). After 0, 60, 90 and 180 days of the treatment, all individuals were clinically evaluated. Additionally, examination of synovial fluid from all of the animals was performed after 0, 60, 90 and 180 days. The CT analysis were performed at day 0 and 180 days after the treatment. The AdMSCs therapy in the case of elbow joint degeneration (OA) decreased the discomfort and reduced accompanying clinical symptoms like pain, stiffness when walking and lameness. In contrast, though the animals from control group showed the improvement during first period of experiment, the OA symptoms reoccurred 90 days after the application of NSAIDs. This work is the first report that not only describes the picture of clinical examination, but is also based on synovial fluid analysis and CT evaluation. The injections of autologous stem cells did not exhibit any adverse reactions, which confirms the safety of this method. Our research confirmed the efficiency of AdMSC injections for the treatment of elbow joint osteoarthritis in dogs, which improve the clinical picture and the patients’ condition, however without the regresses of osteofites.

PDF

___

1. Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, Harman S, Gingerich DA, Harman R: Effect of intraarticular injection of autologous adipose- derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther, 9 (3): 192-200, 2008.
2. Sandell LJ: Etiology of osteoarthritis: Genetics and synovial joint development. Nat Rev Rheumatol, 8 (2): 77-89, 2012.
3. Coleman CM, Curtin C, Barry FP, O’Flatharta C, Murphy JM: Mesenchymal stem cells and osteoarthritis: Remedy or accomplice? Hum Gene Ther, 21 (10): 1239-1250, 2010.
4. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for the medical management of osteoarthritis. Arthritis Rheum, 38 (11): 1535-1540, 1995.
5. Del Bue M, Riccò S, Ramoni R, Conti V, Gnudi G, Grolli S: Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: Their association in vitro and in vivo. Vet Res Commun, 32 (1): 51-55, 2008.
6. Tuglu MI, Ozdal-Kurt F, Koca H, Sarac A, Barut T, Kazanc A: The contribution of differentiated bone marrow stromal cell-loaded biomaterial to treatment in critical size defect model in rats. Kafkas Univ Vet Fak Derg, 16 (5): 783-792, 2010.
7. Marycz K, Krzak-Roś J, Śmieszek A, Grzesiak J, Donesz-Sikorska A: Effect of oxide materials synthesized with sol-gel method on adhesion of mesenchymal stem cells. Przem Chem, 92 (6): 1097-1100, 2013.
8. Fortier LA, Smith RKW: Regenerative medicine for tendinous and ligamentous ınjuries of sport horses. Vet Clin North Am: Equine Pract, 24 (1): 191-201, 2008.
9. Qui Y, Feng G, Yan W: Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep, 39 (5): 5683-5689, 2012.
10. Hodgkiss-Geere HM, Argyle DJ, Corcoran BM, Whitelaw B, Milne E, Bennett D, Argyle SA: Characterisation and differentiation potential of bone marrow derived canine mesenchymal stem cells. Vet J, 194 (3): 361-368, 2012.
11. Lai RC, Chen TS, Lim SK: Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease. Regen Med, 6 (4): 481-492, 2011.
12. Kang JW, Kang KS, Koo HC, Park JR, Choi EW, Park YH: Soluble factors-mediated immunomodulatory effects of canine adipose tissue- derived mesenchymal stem cells. Stem Cells Dev, 17 (4): 681-693, 2008.
13. Grzesiak J, Marycz K, Wrzeszcz K, Czogała J: Isolation and morphological characterisation of ovine adipose-derived mesenchymal stem cells in culture. Int J Stem Cells, 4 (2): 99-104, 2011.
14. Grzesiak J, Marycz K, Czogala J, Wrzeszcz K, Nicpoń J: Comparison of behavior, morphology and morphometry of equine and canine adipose derived mesenchymal stem cells in culture. Int J Morphol, 29 (3): 1012-1017, 2011.
15. Olsson SE: Osteochondrosis in domestic animals. ACTA Radiologic, 358 (Suppl.): 299-305, 1978.
16. Grondalen J: Arthrosis in the elbow joint of young, rapidly growing dogs: Interrelation between clinical radiological and pathoanatomical findings. Nordish Veterinarmedicin, 34, 65-75, 1982.
17. Luna SPL, Basilio AC, Steagall PVM, Machado LP, Moutinho FQ, Takahira RK, Brandao CVS: Evaluation of adverse effects of long- term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res, 68 (3): 258-263, 2007.
18. Guercio A, Di Marco P, Casella S, Cannella V, Russotto L, Purpari G, Di Bella S, Piccione G: Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints. Cell Biol Int, 36 (2): 189-194, 2012.
19. Marycz K, Toker NY, Grzesiak J, Wrzeszcz K, Golonka P: The therapeutic effect of autogenic adipose derived stem cells combined with autogenic platelet rich plasma in tendons disorders in horses in vitro and in vivo research. J Anim Vet Adv, 11 (23): 4324-4331, 2012.
20. Marycz K, Grzesiak J, Wrzeszcz K, Golonka P: Adipose stem cell combined with plasma-based implant bone tissue differentiation in horse suffered phalanx digitalis distalis fracture and in vitro. Vet Med Czech, 57 (12): 610-617, 2012.
21. Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, Gingerich DA, Harman R: Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: A randomized, double-blinded, multicenter, controlled trial. Vet Ther, 8 (4): 272-284, 2007.
22. Ratajczak J, Kucia M, Mierzejewska K, Marlicz W, Pietrzkowski Z, Wojakowski W, Greco NJ, Tendera M, Ratajczak MZ: Paracrine proangiopoietic effects of human umbilical cord blood-derived purified CD133+ cells-implications for stem cell therapies in regenerative medicine. Stem Cells Dev, 22 (3): 422-430, 2013.
23. Nicpoń J, Marycz K, Grzesiak J: The therapeutic effect of adipose derived mesenchymal stem cells injection in horses suffering from bone spavin. Polish J Vet Sci, 16 (4): 753-754, 2013.
24. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ: Membrane-derived microvesicles: Important and under- appreciated mediators of cell-to-cell communication. Leukemia, 20 (9): 1487-1495, 2006.